KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation: 2021-2024

  • Xenon Pharmaceuticals' Accumulated Depreciation rose 19.67% to $13.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $13.5 million, marking a year-over-year increase of 19.67%. This contributed to the annual value of $13.5 million for FY2024, which is 19.67% up from last year.
  • According to the latest figures from Q4 2024, Xenon Pharmaceuticals' Accumulated Depreciation is $13.5 million, which was up 19.67% from $11.3 million recorded in Q4 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Accumulated Depreciation peaked at $13.5 million during Q4 2024, and registered a low of $8.7 million during Q4 2022.
  • For the 3-year period, Xenon Pharmaceuticals' Accumulated Depreciation averaged around $11.1 million, with its median value being $11.3 million (2023).
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first slumped by 34.79% in 2022, then grew by 29.25% in 2023.
  • Xenon Pharmaceuticals' Accumulated Depreciation (Quarterly) stood at $13.3 million in 2021, then tumbled by 34.79% to $8.7 million in 2022, then increased by 29.25% to $11.3 million in 2023, then rose by 19.67% to $13.5 million in 2024.
  • Its Accumulated Depreciation was $13.5 million in Q4 2024, compared to $11.3 million in Q4 2023 and $8.7 million in Q4 2022.